Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Viral load of SARS-CoV-2 in droplets and bioaerosols directly captured during breathing, speaking and coughing.

Tytuł:
Viral load of SARS-CoV-2 in droplets and bioaerosols directly captured during breathing, speaking and coughing.
Autorzy:
Johnson TJ; Department of Engineering, University of Cambridge, Cambridge, UK.
Nishida RT; Department of Mechanical Engineering, University of Alberta, Edmonton, Canada. .
Sonpar AP; Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, Canada.; Alberta Health Services, Alberta, Canada.
Lin YJ; Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Watson KA; Alberta Health Services, Alberta, Canada.; Department of Family Medicine, University of Alberta, Edmonton, Canada.
Smith SW; Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, Canada.; Alberta Health Services, Alberta, Canada.
Conly JM; Alberta Health Services, Alberta, Canada.; Department of Medicine, Microbiology, Immunology and Infectious Diseases, Pathology and Laboratory Medicine, Synder Institute for Chronic Diseases and O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Evans DH; Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Olfert JS; Department of Mechanical Engineering, University of Alberta, Edmonton, Canada. .
Źródło:
Scientific reports [Sci Rep] 2022 Mar 03; Vol. 12 (1), pp. 3484. Date of Electronic Publication: 2022 Mar 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Aerosols*
Cough*
Respiration*
Speech*
Viral Load*
SARS-CoV-2/*isolation & purification
Humans
References:
Int J Infect Dis. 2020 Nov;100:476-482. (PMID: 32949774)
Nature. 2020 Jun;582(7813):557-560. (PMID: 32340022)
J Occup Environ Med. 2015 May;57(5):501-8. (PMID: 25816216)
Science. 2021 May 20;:. (PMID: 34016743)
Int J Infect Dis. 2021 Jul;108:212-216. (PMID: 33901650)
J Hazard Mater. 2021 Jan 15;402:123771. (PMID: 33254782)
Nat Rev Microbiol. 2021 Aug;19(8):528-545. (PMID: 33753932)
Natl Sci Rev. 2020 Sep 28;7(12):1865-1867. (PMID: 34676084)
N Engl J Med. 2020 Apr 16;382(16):1564-1567. (PMID: 32182409)
J Infect Dis. 2021 Jan 4;223(1):23-27. (PMID: 33089317)
Int J Infect Dis. 2021 Sep;110:105-110. (PMID: 34242768)
Epidemiol Infect. 2020 Jul 14;148:e154. (PMID: 32660668)
J Appl Microbiol. 2005;99(6):1422-34. (PMID: 16313415)
Infect Control Hosp Epidemiol. 2020 May;41(5):493-498. (PMID: 32131908)
Clin Infect Dis. 2021 May 18;72(10):e652-e654. (PMID: 32857833)
Open Forum Infect Dis. 2021 Apr 28;8(11):ofab217. (PMID: 34796242)
PLoS One. 2020 Jan 27;15(1):e0227699. (PMID: 31986165)
Nat Commun. 2021 Jan 11;12(1):267. (PMID: 33431879)
N Engl J Med. 2020 Dec 24;383(26):2586-2588. (PMID: 33259154)
J Aerosol Sci. 2021 Feb;152:105693. (PMID: 33078030)
Clin Infect Dis. 2021 Oct 5;73(7):e1870-e1877. (PMID: 32634826)
Sci Rep. 2020 Jul 29;10(1):12732. (PMID: 32728118)
J Infect Dis. 2021 May 20;223(9):1522-1527. (PMID: 33556961)
PLoS One. 2021 Apr 12;16(4):e0249525. (PMID: 33844696)
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666. (PMID: 32442256)
Sci Rep. 2019 Feb 20;9(1):2348. (PMID: 30787335)
J Appl Microbiol. 2016 Mar;120(3):805-15. (PMID: 26751045)
Sci Rep. 2021 Jun 29;11(1):13476. (PMID: 34188082)
Clin Microbiol Rev. 2020 Oct 28;34(1):. (PMID: 33115724)
Open Forum Infect Dis. 2020 Dec 08;8(1):ofaa599. (PMID: 33506066)
J Hyg (Lond). 1946 Sep;44(6):471-9. (PMID: 20475760)
Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
J Occup Environ Hyg. 2015;12(2):107-13. (PMID: 25523206)
Nat Med. 2020 May;26(5):676-680. (PMID: 32371934)
Infect Dis (Lond). 2020 Nov - Dec;52(12):908-912. (PMID: 32845196)
Aerosol Air Qual Res. 2020 Jun;20(6):1167-1171. (PMID: 33424954)
J Infect Dis. 2020 Nov 9;222(11):1798-1806. (PMID: 32905595)
Lancet Microbe. 2021 Jan;2(1):e13-e22. (PMID: 33521734)
Sci Rep. 2020 Nov 11;10(1):19589. (PMID: 33177563)
J Infect. 2021 Jun;82(6):253-259. (PMID: 33774019)
JAMA. 2020 Aug 4;324(5):441-442. (PMID: 32749495)
Thorax. 2021 Jan;76(1):86-88. (PMID: 33097604)
Infect Control Hosp Epidemiol. 2020 Nov;41(11):1258-1265. (PMID: 32507114)
Influenza Other Respir Viruses. 2021 Jul;15(4):554-557. (PMID: 33939268)
Sci Total Environ. 2021 Jan 20;753:141710. (PMID: 32891988)
Nat Commun. 2020 May 29;11(1):2800. (PMID: 32472043)
Lancet Respir Med. 2020 Sep;8(9):914-924. (PMID: 32717211)
PLoS One. 2014 Jul 10;9(7):e102215. (PMID: 25010422)
Infect Control Hosp Epidemiol. 2021 Nov;42(11):1327-1332. (PMID: 33487210)
Grant Information:
Postdoctoral Fellowships Program Natural Sciences and Engineering Research Council of Canada; Research grant for the Infection Prevention and Control (IPC) Pillar. International WHO_ World Health Organization
Substance Nomenclature:
0 (Aerosols)
Entry Date(s):
Date Created: 20220304 Date Completed: 20220314 Latest Revision: 20220314
Update Code:
20240105
PubMed Central ID:
PMC8894466
DOI:
10.1038/s41598-022-07301-5
PMID:
35241703
Czasopismo naukowe
Determining the viral load and infectivity of SARS-CoV-2 in macroscopic respiratory droplets, bioaerosols, and other bodily fluids and secretions is important for identifying transmission modes, assessing risks and informing public health guidelines. Here we show that viral load of SARS-CoV-2 Ribonucleic Acid (RNA) in participants' naso-pharyngeal (NP) swabs positively correlated with RNA viral load they emitted in both droplets >10 [Formula: see text] and bioaerosols <10 [Formula: see text] directly captured during the combined expiratory activities of breathing, speaking and coughing using a standardized protocol, although the NP swabs had [Formula: see text] 10[Formula: see text] more RNA on average. By identifying highly-infectious individuals (maximum of 18,000 PFU/mL in NP), we retrieved higher numbers of SARS-CoV-2 RNA gene copies in bioaerosol samples (maximum of 4.8[Formula: see text] gene copies/mL and minimum cycle threshold of 26.2) relative to other studies. However, all attempts to identify infectious virus in size-segregated droplets and bioaerosols were negative by plaque assay (0 of 58). This outcome is partly attributed to the insufficient amount of viral material in each sample (as indicated by SARS-CoV-2 gene copies) or may indicate no infectious virus was present in such samples, although other possible factors are identified.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies